Retracted: Building on a Strong Foundation to Address a New Era to Help Protect Against Pneumococcal Disease

Chairperson:

Antoni Torres¹

Speakers:

Mário Ramirez,^2,3 Charles Feldman,⁴ Wendy Watson⁵

1. Respiratory Intensive Care Unit, Department of Pneumology and Respiratory Allergy, Hospital Clinic of Barcelona, University of Barcelona, Spain
2. Faculty of Medicine, University of Lisbon, Portugal
3. Molecular Microbiology and Infection Laboratory, Institute of Molecular Medicine, University of Lisbon, Portugal
4. Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa
5. Vaccines Clinical Research, Pfizer, Collegeville, USA

Disclosure:

Torres has received honoraria for speaking engagements or advisory roles for Atriva Pharmaceuticals, Janssen, MSD, Menarini, and Pfizer. Ramirez has received fees for Pfizer speaker bureaus, GlaxoSmithKline expert panels, and Merck Sharp & Dohme speaker bureaus and expert panels. Feldman has received honoraria for speaking engagements or advisory roles for MSD and Pfizer. Watson is a Pfizer employee and holds stock/stock options. The studies in this presentation were funded by Pfizer.

Acknowledgements:

Writing assistance was provided by International Meetings & Science (IMsci), Stamford, Connecticut, USA.

Support:

The symposium and publication of this article were funded by Pfizer, Inc. The views and opinions expressed are exclusively those of the speakers.

Citation:

EMJ Microbiol Infect Dis. 2022;3[Suppl 1] https://doi.org/10.33590/emjmicrobiolinfectdis/IWYH8343.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.